Category: Policy
The Thalion Initiative: A New Non-Profit With Big Ambitions
June 2, 2026
The longevity field remains small and starved for resources, especially the subfield devoted to the fundamental biology of aging, despite near-universal agreement that solving aging requires understanding it first. With
Developing a Drug To Reverse Heart Disease
May 18, 2026
We have spoken with Reason from Repair Biotechnologies about his company’s lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The FDA has granted Repair
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
April 8, 2026
The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing
First Human Cellular Reprogramming Trial Cleared by the FDA
February 6, 2026
Life Biosciences has announced that its trial of cellular reprogramming aimed at two age-related vision diseases has received a go-ahead from the FDA. We spoke with the company’s CSO to
Life Biosciences Announces FDA Clearance of IND for ER-100
February 2, 2026
Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA)
Longevity Policy, Advocacy in the Spotlight at Vitalist Bay
June 20, 2025
Just several years ago, longevity conferences were few and far between. Today, there’s no shortage of them. Happening regularly around the globe, they foster scientific debate and showcase geroscience advances
Another Year of Longevity Advocacy and Journalism
December 23, 2024
The nights are the longest of the year, the holidays are drawing near, and we are back with a festive edition of the lifespan.io editorial. This time, we bring you
Mehmood Khan on Aging Policy and Collaboration
December 3, 2024
I first met Dr. Mehmood Khan in 2022 at the inaugural Longevity Summit Dublin, where organizers Aubrey de Grey and Martin O’Dea made a bold decision to include policy and
FDA RMAT Framework is Win-Win for Gene Therapies
February 20, 2018
Back in November 2017, the FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. Both draft guidance documents had 90-day
The Thalion Initiative: A New Non-Profit With Big Ambitions
June 2, 2026
The longevity field remains small and starved for resources, especially the subfield devoted to the fundamental biology of aging, despite near-universal agreement that solving aging requires understanding it first. With VCs looking for clinical successes and state funding drying up for many projects, some enthusiasts are
Developing a Drug To Reverse Heart Disease
May 18, 2026
We have spoken with Reason from Repair Biotechnologies about his company’s lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The FDA has granted Repair Bio an orphan drug indication, and the company is aiming for clinical trials by mid-2027. Our
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
April 8, 2026
The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing there. If this technique works in resetting the biological age of the human eye, the entire
First Human Cellular Reprogramming Trial Cleared by the FDA
February 6, 2026
Life Biosciences has announced that its trial of cellular reprogramming aimed at two age-related vision diseases has received a go-ahead from the FDA. We spoke with the company’s CSO to get more details. Life Biosciences, the biotech company based on Harvard professor David Sinclair’s research into
Life Biosciences Announces FDA Clearance of IND for ER-100
February 2, 2026
Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ER-100. The IND clearance allows Life Bio
Longevity Policy, Advocacy in the Spotlight at Vitalist Bay
June 20, 2025
Just several years ago, longevity conferences were few and far between. Today, there’s no shortage of them. Happening regularly around the globe, they foster scientific debate and showcase geroscience advances to the world while energetically discussing longevity biotech and regulations. However, one important subfield, working with
Another Year of Longevity Advocacy and Journalism
December 23, 2024
The nights are the longest of the year, the holidays are drawing near, and we are back with a festive edition of the lifespan.io editorial. This time, we bring you some of this year’s highlights and talk about what the future holds for our content. lifespan.io
Mehmood Khan on Aging Policy and Collaboration
December 3, 2024
I first met Dr. Mehmood Khan in 2022 at the inaugural Longevity Summit Dublin, where organizers Aubrey de Grey and Martin O’Dea made a bold decision to include policy and advocacy discussions alongside the traditional focus on longevity research. Like many others in the audience, I
FDA RMAT Framework is Win-Win for Gene Therapies
February 20, 2018
Back in November 2017, the FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. Both draft guidance documents had 90-day comment periods, and we at LEAF joined forces with the Niskanen Center to submit comments to